Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.

Horvat I, Boban A, Zadro R, Antolic MR, Serventi-Seiwerth R, Roncevic P, Radman I, Sertic D, Vodanovic M, Pulanic D, Basic-Kinda S, Durakovic N, Zupancic-Salek S, Vrhovac R, Aurer I, Nemet D, Labar B.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):53-63. doi: 10.1016/j.clml.2018.08.020. Epub 2018 Sep 10.

PMID:
30301673
2.

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017.

Jakšić B, Pejša V, Ostojić-Kolonić S, Kardum-Skelin I, Bašić-Kinda S, Coha B, Gverić-Krečak V, Vrhovac R, Jakšić O, Aurer I, Sinčić-Petričević J, Načinović-Duletić A, Nemet D.

Acta Clin Croat. 2018 Mar;57(1):190-215. doi: 10.20471/acc.2018.57.01.27.

3.

Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.

Federico M, Caballero Barrigón MD, Marcheselli L, Tarantino V, Manni M, Sarkozy C, Alonso-Álvarez S, Wondergem M, Cartron G, Lopez-Guillermo A, Issa D, Morschhauser F, Alcoceba M, Kimby E, Rusconi C, Chamuleau M, Holte H, Lockmer S, Montoto S, Gomes da Silva M, Aurer I, Zucca E, Paszkiewicz-Kozik E, Minoia C, Skrypets T, Blaker YN, Salles G, Coiffier B; Aristotle Consortium.

Lancet Haematol. 2018 Aug;5(8):e359-e367. doi: 10.1016/S2352-3026(18)30090-5. Epub 2018 Jul 4.

PMID:
30078408
4.

Serum chitotriosidase: a circulating biomarker in polycythemia vera.

Krecak I, Gveric-Krecak V, Roncevic P, Basic-Kinda S, Gulin J, Lapic I, Fumic K, Ilic I, Horvat I, Zadro R, Holik H, Coha B, Peran N, Aurer I, Durakovic N.

Hematology. 2018 Dec;23(10):793-802. doi: 10.1080/10245332.2018.1498157. Epub 2018 Jul 11.

PMID:
29993340
5.

Author reply.

Basic-Kinda S, Karlak I, Durakovic N, Lubina ZI, Radman I, Dotlic S, Peric Z, Hude I, Aurer I.

Intern Med J. 2018 Jun;48(6):748-749. doi: 10.1111/imj.13822. No abstract available.

PMID:
29898265
6.

Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.

Dreyling M, Aurer I, Cortelazzo S, Hermine O, Hess G, Jerkeman M, Le Gouill S, Ribrag V, Trněný M, Visco C, Walewski J, Zaja F, Zinzani PL.

Leuk Lymphoma. 2018 Aug;59(8):1814-1828. doi: 10.1080/10428194.2017.1403602. Epub 2017 Nov 27. Review.

PMID:
29172868
7.

High incidence of aseptic hip necrosis in Hodgkin lymphoma patients treated with escalated BEACOPP receiving methylprednisolone.

Basic-Kinda S, Karlak I, Durakovic N, Lubina ZI, Livaja Radman I, Dotlic S, Peric Z, Hude I, Aurer I.

Intern Med J. 2018 May;48(5):523-529. doi: 10.1111/imj.13653.

PMID:
29068514
8.

Unmet needs in the scientific approach to older patients with lymphoma.

Bron D, Aurer I, André MPE, Bonnet C, Caballero D, Falandry C, Kimby E, Soubeyran P, Zucca E, Bosly A, Coiffier B; European Lymphoma Institute (ELI) Group and the EHA SWG “Aging and Hematology”.

Haematologica. 2017 Jun;102(6):972-975. doi: 10.3324/haematol.2017.167619. Review. No abstract available.

9.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

10.

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, Evens AM, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS.

Cancer Discov. 2017 Apr;7(4):369-379. doi: 10.1158/2159-8290.CD-16-0330. Epub 2017 Jan 25.

11.

Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma.

Periša V, Zibar L, Knezović A, Periša I, Sinčić-Petričević J, Aurer I.

Wien Klin Wochenschr. 2017 Jun;129(11-12):411-419. doi: 10.1007/s00508-016-1077-7. Epub 2016 Sep 8.

PMID:
27637206
12.

Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial.

Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, Caillot D, Gaillard I, Bologna S, Ferme C, Lugtenburg PJ, Morschhauser F, Aurer I, Coiffier B, Meyer R, Seftel M, Wolf M, Glimelius B, Sureda A, Mounier N.

J Clin Oncol. 2016 Jun 10;34(17):2028-36. doi: 10.1200/JCO.2015.64.5648. Epub 2016 Apr 25.

PMID:
27114593
13.

High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.

Aurer I, Nemet D, Mitrović Z, Dujmović D, Bašić-Kinda S, Radman I, Sertić D, Šantek F, Kralik M, Dotlić S, Mazić S, Labar B.

Ann Hematol. 2016 Jun;95(7):1129-36. doi: 10.1007/s00277-016-2676-0. Epub 2016 Apr 22.

PMID:
27103009
14.

[Mediastinal tumors].

Kukulj S, Popović F, Drpa G, Budimir B, Jakopović M, Čučević B, Koršić M, Samaržija M, Aurer I, Gnjidić M, Ramać JP.

Lijec Vjesn. 2015 Jul-Aug;137(7-8):252-6. Croatian. No abstract available.

PMID:
26502679
15.

Precision medicine in diffuse large B-cell lymphoma: hitting the target.

Vermaat JS, Pals ST, Younes A, Dreyling M, Federico M, Aurer I, Radford J, Kersten MJ; EHA Lymphoma Group, a Scientific Working Group of the European Hematology Association.

Haematologica. 2015 Aug;100(8):989-93. doi: 10.3324/haematol.2015.128371. No abstract available.

16.

FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.

Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group.

Ann Oncol. 2015 Oct;26(10):2155-61. doi: 10.1093/annonc/mdv317. Epub 2015 Jul 27.

PMID:
26216382
17.

Simultaneous presentation of oral and skin anaplastic large T-cell lymphoma.

Milenović A, Boras VV, Ilić I, Dotlić S, Aurer I, Kinda SB, Mayer M, Mikulić M, Tomasović-Loncarić C, Skrinjar I.

Acta Clin Croat. 2014 Jun;53(2):246-51.

PMID:
25163243
18.

Multiparameter flow cytometry is necessary for detection, characterization and diagnostics of composite mature B-cell lymphoproliferative neoplasms.

Perković S, Bašić-Kinda S, Aurer I, Ugrina I, Duletić-Načinović A, Lozić D, Batinić D.

Int J Hematol. 2013 Nov;98(5):589-96. doi: 10.1007/s12185-013-1432-7. Epub 2013 Sep 24.

PMID:
24061774
19.

[Lymphoma diagnosis and treatment - second Croatian consensus].

Aurer I, Gasparov S, Kralik M, Balenović A, Huić D, Santek F, Duletić-Nacinović A, Pejsa V, Ostojić-Kolonić S, Grah JJ; Croatian Society for Hematology and Transfusion; Croatian Coooperative Group for Treatment of Hematologic Diseases; Croatian Medical Society.

Lijec Vjesn. 2013 Mar-Apr;135(3-4):63-76. Croatian.

PMID:
23671972
20.

Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).

Aurer I, Bašić-Kinda S, Radman I, Ilić I, Grah JJ.

Ann Hematol. 2014 Jan;93(1):177-8. doi: 10.1007/s00277-013-1771-8. Epub 2013 May 2. No abstract available.

PMID:
23636314
21.

Demyelination after primary central nervous system lymphoma; reversed ‘sentinel’.

Barun B, Kinda S, Aurer I, Žarković K, Adamec I, Habek M.

Can J Neurol Sci. 2012 Nov;39(6):843-4. No abstract available.

PMID:
23230617
22.

Epstein-Barr virus-negative aggressive natural killer-cell leukaemia with high P-glycoprotein activity and phosphorylated extracellular signal-regulated protein kinases 1 and 2.

Perkovic S, Basic-Kinda S, Gasparovic V, Krznaric Z, Babel J, Ilic I, Aurer I, Batinic D.

Hematol Rep. 2012 Jul 11;4(3):e16. doi: 10.4081/hr.2012.e16. Epub 2012 Sep 4.

23.

Hepatosplenic αβ T-cell lymphoma arising after long-term azathioprine therapy successfully treated with allogeneic bone marrow transplant.

Bašić Kinda S, Duraković N, Dotlić S, Serventi Seiwerth R, Davidović Mrsić S, Dubravčić K, Aurer I.

Leuk Lymphoma. 2013 Jun;54(6):1334-5. doi: 10.3109/10428194.2012.740563. Epub 2012 Nov 26. No abstract available.

PMID:
23083012
24.

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.

Dreyling M, Kluin-Nelemans HC, Beà S, Klapper W, Vogt N, Delfau-Larue MH, Hutter G, Cheah C, Chiappella A, Cortelazzo S, Pott C, Hess G, Visco C, Vitolo U, Klener P, Aurer I, Unterhalt M, Ribrag V, Hoster E, Hermine O; European MCL Network.

Leuk Lymphoma. 2013 Apr;54(4):699-707. doi: 10.3109/10428194.2012.733882. Epub 2012 Nov 21. Review.

PMID:
23020649
25.

Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma/leukemia.

Dujmovic D, Aurer I, Radman I, Serventi-Seiwerth R, Dotlic S, Stern-Padovan R, Dubravcic K, Santek F, Labar B.

Acta Haematol. 2012;127(2):115-7. doi: 10.1159/000334705. Epub 2011 Dec 31. No abstract available.

PMID:
22212303
26.

(Mis)placed central venous catheter in the left superior intercostal vein.

Padovan RS, Paar MH, Aurer I.

Radiol Oncol. 2011 Mar;45(1):27-30. doi: 10.2478/v10019-010-0043-7. Epub 2010 Sep 29.

27.

Changing therapeutic landscape--the last decade.

Aurer I.

Transfus Apher Sci. 2011 Apr;44(2):155-9. doi: 10.1016/j.transci.2011.01.010. Epub 2011 Feb 12. Review.

PMID:
21320799
28.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.

J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25.

PMID:
20975066
29.

Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).

Aurer I, Eghbali H, Raemaekers J, Khaled HM, Fortpied C, Baila L, van der Maazen RW; EORTC Lymphoma Group.

Eur J Haematol. 2011 Feb;86(2):111-6. doi: 10.1111/j.1600-0609.2010.01540.x. Epub 2010 Dec 22.

PMID:
20942843
30.

Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP.

Mitrović Z, Ilić I, Aurer I, Kinda SB, Radman I, Dotlić S, Ajduković R, Labar B.

Pathol Oncol Res. 2011 Jun;17(2):243-7. doi: 10.1007/s12253-010-9304-4. Epub 2010 Sep 18.

PMID:
20853074
31.

FNA based diagnosis of head and neck nodal lymphoma.

Kuvezdić KG, Aurer I, Ries S, Sucić M, Glamocak MM, Ilić I, Basić-Kinda S, Radman I, Labar B.

Coll Antropol. 2010 Mar;34(1):7-12.

PMID:
20437634
32.

NK cell lymphoma, nasal type, with massive lung involvement: a case report.

Morovic A, Aurer I, Dotlic S, Weisenburger DD, Nola M.

J Hematop. 2010 Mar 24;3(1):19-22. doi: 10.1007/s12308-009-0050-z.

33.

[Twenty years of severe aplastic anemia treatment at Department of Hematology, University Department of Medicine, Zagreb University Hospital Center, Zagreb, Croatia].

Mrsić M, Seiwerth RS, Labar B, Bogdanić V, Nemet D, Duraković N, Mikulić M, Sertić D, Aurer I, Radman I, Zupancić-Salek S.

Acta Med Croatica. 2009 Jun;63(3):209-14. Croatian.

PMID:
19827347
34.

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab.

Ilić I, Mitrović Z, Aurer I, Bašić-Kinda S, Radman I, Ajduković R, Labar B, Dotlić S, Nola M.

Int J Hematol. 2009 Jul;90(1):74-80. doi: 10.1007/s12185-009-0353-y. Epub 2009 Jun 3.

PMID:
19495929
35.

CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.

Mitrovic Z, Ilic I, Nola M, Aurer I, Sonicki Z, Basic-Kinda S, Radman I, Ajdukovic R, Labar B.

Clin Lymphoma Myeloma. 2009 Apr;9(2):133-7. doi: 10.3816/CLM.2009.n.033.

PMID:
19406723
36.

Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.

Aurer I, Mitrović Z, Nemet D, Radman I, Sertić D, Serventi-Seiwerth R, Stern-Padovan R, Santek F, Nola M, Mrsić M, Labar B.

J Chemother. 2008 Oct;20(5):640-4.

PMID:
19048695
37.

[Primary central nervous system lymphoma--a single center experience].

Mitrović Z, Radman I, Aurer I, Petranović D, Santek F, Labar B.

Lijec Vjesn. 2007 Dec;129(12):391-5. Croatian.

PMID:
18383741
38.

[Diagnosis and therapy of lymphomas--Croatian consensus].

Aurer I, Dominis M, Stern-Padovan R, Huić D, Santek F.

Lijec Vjesn. 2007 May;129(5):111-7. Review. Croatian. No abstract available.

PMID:
17695189
39.

FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.

Mitroviç Z, Aurer I, Radman I, Ajdukoviç R, Sertiç J, Labar B.

Haematologica. 2007 Jul;92(7):998-9.

40.

Aberrant glycosylation of Igg heavy chain in multiple myeloma.

Aurer I, Lauc G, Dumić J, Rendić D, Matisić D, Milos M, Heffer-Lauc M, Flogel M, Labar B.

Coll Antropol. 2007 Mar;31(1):247-51.

PMID:
17598409
41.

[Treatment of hairy cell leukemia with cladribine].

Aurer I, Mitrović Z, Kovacević-Metelko J, Radman I, Basić-Kinda S, Gjadrov-Kuvezdić K, Jakić-Razumović J, Dubravcić K, Ries S, Nola M, Zupancic-Salek S, Labar B.

Lijec Vjesn. 2007 Mar-Apr;129(3-4):80-3. Croatian.

PMID:
17557550
42.

Primary cardiac lymphoma presenting as atrial flutter and total heart block.

Bulum J, Banfić L, Strozzi M, Aurer I, Jelasić D.

Heart Vessels. 2007 Jan;22(1):52-4. Epub 2007 Jan 26.

PMID:
17285447
43.

[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].

Aurer I, Huić D, Zuvić M, Sever-Prebilić M, Ajduković R, Radman I, Skare-Librenjak L, Ostojić-Kolonić S, Labar B.

Lijec Vjesn. 2006 Jul-Aug;128(7-8):224-7. Croatian.

PMID:
17087138
44.

[Rituximab in the treatment of B-cell non-Hodgkin lymphoma].

Mitrović Z, Aurer I.

Lijec Vjesn. 2006 Jan-Feb;128(1-2):36-42. Review. Croatian.

PMID:
16640226
45.

The value of F-18 FDG triple-head coincidence PET in the posttreatment evaluation of patients with lymphoma.

Huić D, Mutvar A, Radman I, Grosev D, Labar B, Zuvić M, Dodig D, Aurer I, Nemet D.

Clin Nucl Med. 2006 May;31(5):275-8. No abstract available.

PMID:
16622336
46.

Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.

Aurer I, Radman I, Nemet D, Zupancić-Salek S, Bogdanić V, Mrsić M, Sertić D, Labar B.

Onkologie. 2005 Nov;28(11):567-71.

PMID:
16249642
47.

[Rituximab in the treatment of indolent non-Hodgkin's lymphoma].

Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B.

Lijec Vjesn. 2004 Nov-Dec;126(11-12):307-11. Croatian.

PMID:
16082888
48.

Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.

Sucić M, Zadro R, Burazer B, Labar B, Nemet D, Mrsić M, Aurer I, Mrsić S, Hitrec V, Boban D, Marković-Glamocak M, Batinić D, Uzarević B, Stavljenić-Rukavina A.

J Hematother Stem Cell Res. 2002 Dec;11(6):941-50.

PMID:
12590709
49.

Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.

Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B.

Croat Med J. 2002 Oct;43(5):555-60.

50.

Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.

Aurer I, Duraković N, Radman I, Nemet D, Zupancić-Salek S, Kovacević-Metelko J, Bogdanić V, Sertić D, Mrsić M, Mikulić M, Labar B.

Croat Med J. 2002 Oct;43(5):550-4.

Supplemental Content

Support Center